New Hydrogen Particles Show Promise for Treating Ulcerative Colitis
- Authors
- Na Yu, Jingwen Xu, Jie Fan, Huimin Gao, Ting Wu, Yunfeng Zhu, Jing Xu, Xiaolin Li, Huae Xu, Xiaowei Lu
- Journal
- International Journal of Pharmaceutics: X
- Year
- 2025
- DOI
- 10.1016/j.ijpx.2025.100429
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Ulcerative Colitis
- Body System
- Digestive System
TL;DR
A novel MgH₂@MgO hydrogen-releasing particle effectively scavenges ROS, suppresses NF-κB signaling, and alleviates ulcerative colitis, offering a low-toxicity therapeutic strategy for long-term inflammation control.
Key Finding
In mouse models of ulcerative colitis, magnesium hydride particles that release hydrogen effectively reduced harmful reactive oxygen species and suppressed inflammation by blocking the NF-κB signaling pathway.
Summary
Ulcerative colitis is a chronic inflammation of the intestines that causes damage from harmful molecules called reactive oxygen species (ROS). Researchers tested a new particle made of magnesium hydride that releases hydrogen gas in the body. In mouse studies, this particle reduced harmful ROS levels, decreased inflammation, and improved intestinal damage by blocking a specific inflammation pathway called NF-κB.
Practical Takeaway
This is early-stage research in mice only, so results cannot yet be applied to humans with ulcerative colitis. The study suggests hydrogen delivery through this novel particle form may have potential as a future treatment option, but human clinical trials would be needed to determine safety and effectiveness. Anyone with ulcerative colitis should continue working with their healthcare provider rather than self-treating based on this animal research.
Abstract
Ulcerative colitis (UC) is a diffuse chronic inflammation in the superficial intestine. Excessive accumulation of reactive oxygen species (ROS) leads to the of the colorectal damage. As the anti-inflammation therapy needs to be last for at least 3-5 years, the drugs demand less toxicity. However, current treatments in the clinic are often accompanied by unavoidable adverse side effects. Hydrogen is a nontoxic antioxidant reagent with excellent permeability of biomembranes, which shows the potential in treating UC. A novel simply designed hydrogen storage particle, Magnesium Hydride (MgH2) particle with an outer shell of passivated Magnesium oxide (MgO), was constructed in the current study to enable the safe and controlled release of hydrogen. This studies demonstrated that magnesium hydride particle (MgH2@MgO) was effective in scavenging excessive ROS, relieving the inflammation, and reversing the progression of UC through inhibiting the NF-κB signaling pathway, which provided the experimental evidence for the clinical prevention and therapy of UC.